Tumors with low-cytotoxicity immunophenotypes have disrupted the cancer-immunity cycle due to genetic alterations in the WNT– β-catenin pathway and upregulation of TGF-β and Hedgehog signaling pathways, which drive immune evasion33,34. This evidence concerns the gene TGFB1 and cancer.